2024-09-11 - Analysis Report
##  ABT Stock Analysis Report

This report provides an analysis of Abbott Laboratories (ABT), a multinational healthcare company that develops, manufactures, and markets a wide range of health care products including medical devices, pharmaceuticals, and nutrition products.

### Performance Overview:

**1.  Return Rate Comparison:**

* **ABT's Cumulative Return:** 45.65%
* **S&P 500 (VOO) Cumulative Return:** 83.37%
* **Difference:** -37.72%
* **Relative Divergence:** 25.54% (This indicates ABT has underperformed compared to the S&P 500 over the historical period, but its relative performance is in the 25.54th percentile).

**2. Recent Price Movements:**

* **Closing Price:** $116.43
* **5-Day Moving Average:** $114.49
* **20-Day Moving Average:** $112.20
* **60-Day Moving Average:** $107.43 
   
   This suggests a recent uptrend as the closing price is above all the moving averages, indicating potential momentum. 

**3. Technical Indicators:**

* **RSI:** 71.39 - This indicates the stock is in overbought territory, suggesting a potential short-term correction.
* **PPO:** 0.07 - A positive PPO value indicates a bullish momentum. 
* **Delta_Previous_Relative_Divergence:**  5.75 - A positive value suggests short-term upward price movement.
* **Expected Return:** 23.69% - This is the estimated 5-year potential return based on current investment. 

**4.  Recent Earnings & Outlook:**

| Date       | EPS    | Revenue    |
|-------------|--------|------------|
| 2024-07-31 | 0.74   | 10.38 B$  |
| 2024-05-02 | 0.7    | 9.96 B$   |
| 2023-11-01 | 0.82   | 10.14 B$  |
| 2023-08-03 | 0.79   | 9.98 B$   |
| 2024-07-31 | 0.79   | 9.98 B$   |

The most recent earnings report for Q2 2024 shows EPS of $0.74, exceeding analyst estimates of $0.70, and revenue of $10.38 Billion, also beating estimates of $10.19 Billion.  This indicates continued strong performance for the company. 


###  Summary: 

ABT has underperformed the S&P 500 in the long term, but recent price action shows positive momentum with a current uptrend.  While some technical indicators suggest a potential short-term correction, overall the stock seems to be in a bullish trend. The recent positive earnings report further supports this view. The expected 5-year return is attractive and could make it a potential investment for long-term investors seeking exposure to the healthcare sector. 
